Literature DB >> 34915509

Surgery in Autoimmune Pancreatitis.

Sara Nikolic1,2, Poya Ghorbani3,4, Raffaella Pozzi Mucelli3,5, Sam Ghazi6, Francisco Baldaque-Silva1,4, Marco Del Chiaro3,4,7, Ernesto Sparrelid3,4, Caroline S Verbeke6,8, J-Matthias Löhr3,4, Miroslav Vujasinovic1,4.   

Abstract

INTRODUCTION: Autoimmune pancreatitis (AIP) is a disease that may mimic malignant pancreatic lesions both in terms of symptomatology and imaging appearance. The aim of the present study is to analyze experiences of surgery in patients with AIP in one of the largest European cohorts. PATIENTS AND METHODS: We performed a single-center retrospective study of patients diagnosed with AIP at the Department of Abdominal Diseases at Karolinska University Hospital in Stockholm, Sweden, between January 2001 and October 2020.
RESULTS: There were 159 patients diagnosed with AIP, and among them, 35 (22.0%) patients had surgery: 20 (57.1%) males and 15 (42.9%) females; median age at surgery was 59 years (range 37-81). Median follow-up period after surgery was 50 months (range 1-235). AIP type 1 was diagnosed in 28 (80%) patients and AIP type 2 in 7 (20%) patients. Malignant and premalignant lesions were diagnosed in 8 (22.9%) patients for whom AIP was not the primary differential diagnosis, but in all cases, it was described as a simultaneous finding and recorded in retrospective analysis in histological reports of surgical specimens.
CONCLUSIONS: Diagnosis of AIP is not always straightforward, and in some cases, it is not easy to differentiate it from the malignancy. Surgery is generally not indicated for AIP but might be considered in patients when suspicion of malignant/premalignant lesions cannot be excluded after complete diagnostic workup.
© 2021 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Autoimmune pancreatitis; IgG4; Pancreatic cancer; Surgery

Mesh:

Year:  2021        PMID: 34915509      PMCID: PMC8985041          DOI: 10.1159/000521490

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  23 in total

1.  Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis.

Authors:  Flavia D Mendes; Roberta Jorgensen; Jill Keach; Jerry A Katzmann; Thomas Smyrk; Jessica Donlinger; Suresh Chari; Keith D Lindor
Journal:  Am J Gastroenterol       Date:  2006-07-27       Impact factor: 10.864

Review 2.  United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU).

Authors:  J Matthias Löhr; Enrique Dominguez-Munoz; Jonas Rosendahl; Marc Besselink; Julia Mayerle; Markus M Lerch; Stephan Haas; Fatih Akisik; Nikolaos Kartalis; Julio Iglesias-Garcia; Jutta Keller; Marja Boermeester; Jens Werner; Jean-Marc Dumonceau; Paul Fockens; Asbjorn Drewes; Gürlap Ceyhan; Björn Lindkvist; Joost Drenth; Nils Ewald; Philip Hardt; Enrique de Madaria; Heiko Witt; Alexander Schneider; Riccardo Manfredi; Frøkjer J Brøndum; Sasa Rudolf; Thomas Bollen; Marco Bruno
Journal:  United European Gastroenterol J       Date:  2017-01-16       Impact factor: 4.623

3.  IgG4-related disease-experience of 100 consecutive cases from a specialist centre.

Authors:  Adrian C Bateman; Emma L Culver
Journal:  Histopathology       Date:  2017-01-24       Impact factor: 5.087

4.  International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology.

Authors:  Tooru Shimosegawa; Suresh T Chari; Luca Frulloni; Terumi Kamisawa; Shigeyuki Kawa; Mari Mino-Kenudson; Myung-Hwan Kim; Günter Klöppel; Markus M Lerch; Matthias Löhr; Kenji Notohara; Kazuichi Okazaki; Alexander Schneider; Lizhi Zhang
Journal:  Pancreas       Date:  2011-04       Impact factor: 3.327

5.  Risk of Cancer in Patients with Autoimmune Pancreatitis: A Single-Center Experience from Germany.

Authors:  Alexander Schneider; Michael Hirth; Markus Münch; Christel Weiss; J Matthias Löhr; Matthias P Ebert; Roland H Pfützer
Journal:  Digestion       Date:  2017-02-23       Impact factor: 3.216

Review 6.  Addressing the challenges of pancreatic cancer: future directions for improving outcomes.

Authors:  Manuel Hidalgo; Stefano Cascinu; Jörg Kleeff; Roberto Labianca; J-Matthias Löhr; John Neoptolemos; Francisco X Real; Jean-Luc Van Laethem; Volker Heinemann
Journal:  Pancreatology       Date:  2014-10-17       Impact factor: 3.996

Review 7.  Autoimmune pancreatitis: pathological, clinical, and immunological features.

Authors:  Günter Klöppel; Jutta Lüttges; Matthias Löhr; Giuseppe Zamboni; Daniel Longnecker
Journal:  Pancreas       Date:  2003-07       Impact factor: 3.327

8.  Immunoglobulin G subtypes-1 and 2 differentiate immunoglobulin G4-associated sclerosing cholangitis from primary sclerosing cholangitis.

Authors:  Miroslav Vujasinovic; Pia Maier; Hartwig Maetzel; Roberto Valente; Raffaella Pozzi-Mucelli; Carlos F Moro; Stephan L Haas; Karouk Said; Caroline S Verbeke; Patrick Maisonneuve; J-Matthias Löhr
Journal:  United European Gastroenterol J       Date:  2020-04-29       Impact factor: 4.623

9.  When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery.

Authors:  Horacio J Asbun; Kevin Conlon; Laureano Fernandez-Cruz; Helmut Friess; Shailesh V Shrikhande; Mustapha Adham; Claudio Bassi; Maximilian Bockhorn; Markus Büchler; Richard M Charnley; Christos Dervenis; Abe Fingerhutt; Dirk J Gouma; Werner Hartwig; Clem Imrie; Jakob R Izbicki; Keith D Lillemoe; Miroslav Milicevic; Marco Montorsi; John P Neoptolemos; Aken A Sandberg; Michael Sarr; Charles Vollmer; Charles J Yeo; L William Traverso
Journal:  Surgery       Date:  2014-01-02       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.